Which bacteria are reported to reverse tigecycline’s effects?
The question as written is ambiguous, but in practice it usually refers to strains that can grow despite tigecycline exposure, or strains whose susceptibility is altered (for example, by resistance mechanisms). From the information provided, no specific bacterial strains, species, or isolates are listed that reverse tigecycline’s impact.
What does “reverse tigecycline’s impact” usually mean in research?
Researchers typically use “reverse” to mean one of these:
- The strain shows tigecycline tolerance or resistance (growth continues despite treatment).
- A genetic change (loss or gain of a gene) restores susceptibility in a previously resistant strain.
- A specific resistance mechanism is counteracted (for example, by blocking efflux or restoring permeability), making tigecycline work again.
What strain-specific details are needed to answer precisely?
To name the correct strains, the missing context is:
- The study or paper (title, DOI, or link)
- The organism group (e.g., Enterobacterales, Acinetobacter baumannii, Staphylococcus aureus)
- Whether you mean “reverse” as in genetic reversal (mutant vs. wild type) or treatment reversal (one strain outcompetes another)
- The experimental setup (MIC shift, time-kill, knockout/overexpression, etc.)
If you paste the excerpt or share the paper/study you’re working from, I can extract the exact strains and the mechanism it attributes to tigecycline “reversal.”